Market

At buffalo-bio, we are dedicated to providing groundbreaking solutions to global health problems. We are focused on developing innovative treatments for Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition in which the lungs become severely inflamed.

Currently, there are no therapies available that effectively reduce the mortality rate associated with ARDS, but our team is working tirelessly to develop treatments that can improve the lives of those affected by this condition. We are passionate about providing medical solutions that have a positive impact on the lives of our patients.

Opportunity:

The global lung injury market was valued at $1.58 billion 2020 and is projected to reach $2.42 billion by 2030 registering a CAGR of 4.20% from 2021 to 2030.
ARDS has a mortality rate greater than 50 percent.
Approximately one in six COVID-19 patients have difficulty breathing, and about 40% of these patients then develop acute respiratory distress syndrome (ARDS).
Estimated mortality rate for patients with severe COVID-19-related ARDS is 80%

Unmeet need:

There is no pharmacologic therapy for ARDS with effective reduction of either short-term or long-term mortality.